FDA extends digoxin elixir NDA deadline
Executive Summary
FDA extends deadline for companies to have an approved application for digoxin elixir from June 28 to Dec. 28. The extension was made because "it now appears that...there may not be any manufacturers prepared to market digoxin elixir under an approved application," a 1notice published in the June 29 Federal Register states. FDA set the original deadline in a final rule published June 28, 2002, which also required NDAs for digoxin tablets (2"The Pink Sheet" July 1, 2002, p. 12)...
You may also be interested in...
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.